Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Eur J Cancer Care (Engl) ; 19(4): 554-7, 2010 Jul.
Article in English | MEDLINE | ID: mdl-19709172

ABSTRACT

Early gastric cancer (EGC) is defined as an adenocarcinoma confined to the gastric mucosa or submucosa, regardless of the presence of lymph node metastases. Early gastric cancer carries an excellent prognosis, with a 5-year survival rate at least 85% in most series. However, there are rare cases where distant metastases exist. Bone metastases are rare in gastric cancer; osteoblastic bone metastases are even rarer. We report a patient with EGC (mucosal) and synchronous osteosclerotic bone metastasis. To our knowledge, this is the first reported case of submucosal EGC with synchronous bone metastases. The patient was operated and he received adjuvant chemotherapy and radiotherapy. He died 18 months after gastric surgery from generalized disease.


Subject(s)
Adenocarcinoma/secondary , Bone Neoplasms/secondary , Stomach Neoplasms/pathology , Adenocarcinoma/drug therapy , Adenocarcinoma/radiotherapy , Bone Neoplasms/drug therapy , Bone Neoplasms/radiotherapy , Chemotherapy, Adjuvant , Gastric Mucosa/metabolism , Humans , Male , Middle Aged , Treatment Outcome
3.
Eur J Cancer Care (Engl) ; 14(1): 70-4, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15698388

ABSTRACT

Squamous cell carcinoma of the colon and rectum are extremely rare neoplasms. Many questions regarding their histogenesis and biological behaviour remain unanswered. Surgery is the most effective therapy, and adjuvant chemotherapy and radiotherapy should be considered, especially for node-positive patients. We present a patient with squamous cell carcinoma of the middle rectum who underwent abdominoperineal resection and postoperative adjuvant chemotherapy. The pertinent literature is reviewed.


Subject(s)
Carcinoma, Squamous Cell , Rectal Neoplasms , Aged , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Chemotherapy, Adjuvant/methods , Humans , Male , Rectal Neoplasms/drug therapy , Rectal Neoplasms/pathology , Rectal Neoplasms/surgery , Treatment Outcome
5.
Acta Gastroenterol Belg ; 67(4): 355-7, 2004.
Article in English | MEDLINE | ID: mdl-15727081

ABSTRACT

Trichloroethylene (TCE) is an organic solvent used in a variety of industries for more than 60 years. Several adverse events following acute or chronic exposure to trichloroethylene have been reported. However, TCE-induced hepatitis is very rare. We present the case of a 55-year old male who was presented with anorexia, fatigue and upper abdominal discomfort. Routine laboratory examination revealed marked elevation of liver enzyme values. All possible causes of hepatitis were ruled out. The patient has been working as a shoemaker, in a small room of a basement, with insufficient air-exchange; during the last 5 years he used daily a glue containing 1,1,1 trichloroethylene. The diagnosis of hepatitis was confirmed by liver biopsy. The offending agent was withdrawn. Three months later, he was "feeling well" and liver enzyme values had returned to normal. Six months after the initial biopsy, a second liver biopsy was performed and histology was markedly improved. Workers exposed to hazardous chemicals, such as trichloroethylene, must have periodic follow-up examinations. Good work practices are very important when using toxic substances. In patients whose initial diagnostic workout is negative for common causes of acute or chronic hepatitis, toxic causes should be considered, with emphasis on patient's job and working conditions.


Subject(s)
Chemical and Drug Induced Liver Injury/etiology , Liver/pathology , Occupational Exposure/adverse effects , Solvents/adverse effects , Trichloroethylene/adverse effects , Adhesives/adverse effects , Chemical and Drug Induced Liver Injury/pathology , Humans , Liver/drug effects , Male , Middle Aged , Time Factors
6.
J Clin Gastroenterol ; 36(4): 325-8, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12642739

ABSTRACT

GOALS: To establish whether omeprazole plus azithromycin in association with either amoxicillin or tinidazole is effective in curing Helicobacter pylori infection in dyspeptic patients. BACKGROUND: Many antibiotics in combination with antisecretory drugs have been used in an attempt to find the optimal regimen for eradication of H. pylori. Azithromycin is a macrolide that achieves high concentrations in gastric tissue after a single 500-mg oral dose. STUDY: A total of 160 consecutive symptomatic patients with H. pylori received omeprazole 20 mg twice daily for 1 week, azithromycin 500 mg/d for 3 days, and were randomly assigned to either amoxicillin 1 g twice daily (OAzAm group, n = 80) for 1 week or tinidazole 500 mg twice daily for 3 days (OAzT group, n = 80). H. pylori status was assessed by rapid urease test and histology at entry and by histology and (13)C-urea breath test after the end of the therapy. RESULTS: H. pylori was eradicated in 62.5% of patients in the OAzAm group (intention to treat [ITT] 62.5%) and in 71.2% of patients in the OAzT group (ITT 71.2%). CONCLUSIONS: Although the compliance was excellent and the side effects negligible, the regimens used were partially effective for the eradication of H. pylori.


Subject(s)
Drug Therapy, Combination/administration & dosage , Gastrointestinal Diseases/drug therapy , Helicobacter Infections/drug therapy , Helicobacter pylori/drug effects , Omeprazole/administration & dosage , Tinidazole/administration & dosage , Adult , Aged , Amoxicillin/administration & dosage , Azithromycin/administration & dosage , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , Gastrointestinal Diseases/microbiology , Helicobacter Infections/diagnosis , Helicobacter pylori/isolation & purification , Humans , Male , Middle Aged , Probability , Prospective Studies , Treatment Outcome
7.
Respir Med ; 96(8): 553-8, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12195834

ABSTRACT

Proinflammatory cytokines Interleukin-1 beta (IL-1 beta) and Interleukin-6 (IL-6) play a significant role in the pathogenetic processes related to various malignant and inflammatory conditions. Leukocytosis, thrombocytosis and increased acute phase protein levels are part of a systemic inflammatory response. In this study, we measured the concentrations of IL-1 beta, IL-6 and ferritin as well as hemoglobin, lactate dehydrogenase (LDH), C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in 23 patients (male 15, female 8, median age 68 years) with lung cancer and reactive thrombocytosis (LCRT), in 27 (male 18, female 9, median age 64 years) with benign inflammatory lung disorder (BILD) and 18 (male 10, female 8, median age 62 years) lung cancer patients with a normal platelet count (LCNP). IL-1 beta levels were significantly higher in the three patient groups in comparison with control subjects (P < 0.001) but without significant difference among the three patient groups. IL-6 was higher in all three patients groups but only in the BILD group it was significantly higher than the control group (P < 0.05). However, no significant difference in IL-6 serum levels was found between the two lung cancer groups. CRP and LDH were significantly higher in the LCRT group in comparison with the other two patient groups (P < 0.01 and 0.001, respectively), while ferritin was higher in both lung cancer groups in comparison with the BILD group (P < 0.001). Our data suggest that in lung cancer patients, reactive thrombocytosis is part of the systemic inflammatory reaction for which IL-1 beta and IL-6 may be intermediate but not independent mediators.


Subject(s)
Interleukin-1/blood , Interleukin-6/blood , Lung Neoplasms/complications , Thrombocytosis/etiology , Adult , Aged , Blood Sedimentation , Case-Control Studies , Female , Humans , Lung Neoplasms/blood , Male , Middle Aged , Platelet Count , Pneumonia/blood , Pneumonia/complications , Thrombocytosis/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...